These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1487 related articles for article (PubMed ID: 7808487)

  • 21. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.
    Tsimberidou AM; Stavroyianni N; Viniou N; Papaioannou M; Tiniakou M; Marinakis T; Skandali A; Sakellari I; Yataganas X;
    Cancer; 2003 Apr; 97(7):1721-31. PubMed ID: 12655529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
    Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
    Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
    Wahlin A; Brinch L; Hörnsten P; Evensen SA; Oberg G; Simonsson B; Hedenus M
    Eur J Haematol; 1997 Apr; 58(4):233-40. PubMed ID: 9186533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Keating S; de Witte T; Suciu S; Willemze R; Hayat M; Labar B; Resegotti L; Ferrini PR; Caronia F; Dardenne M; Solbu G; Petti MC; Vegna ML; Mandelli F; Zittoun RA
    Br J Haematol; 1998 Sep; 102(5):1344-53. PubMed ID: 9753069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
    Liso V; Iacopino P; Avvisati G; Petti MC; Broccia G; Carotenuto M; Falda M; Fazi P; Lazzarino M; Leoni P; Mirto S; Pucci G; Nobile F; Nosari AM; Specchia G; Stasi R; Tabilio A; Mandelli F
    Leukemia; 1996 Sep; 10(9):1443-52. PubMed ID: 8751460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Centre effect on treatment outcome for patients with untreated acute myelogenous leukaemia? An analysis of the AML 8A Study of the Leukemia Cooperative Group of the EORTC and GIMEMA. European Organization for Research and Treatment of Cancer (EORTC) Leukemia Cooperative Group and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA).
    Keating S; de Witte T; Suciu S; Mandelli F; Damasio E; Willemze R; Morra E; Amadori S; Dardenne M; Vegna ML; Zittoun RA
    Eur J Cancer; 1999 Oct; 35(10):1440-7. PubMed ID: 10673975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
    Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
    Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia.
    Kersey JH; Weisdorf D; Nesbit ME; LeBien TW; Woods WG; McGlave PB; Kim T; Vallera DA; Goldman AI; Bostrom B
    N Engl J Med; 1987 Aug; 317(8):461-7. PubMed ID: 3302708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
    Harousseau JL; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall JF; Milpied N; Desablens B; Guyotat D; Herve P
    Leukemia; 1992; 6 Suppl 2():120-3. PubMed ID: 1578912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).
    Oosterveld M; Suciu S; Verhoef G; Labar B; Belhabri A; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Zittoun R; Hess U; Anak O; Beeldens F; Willemze R; de Witte T
    Leukemia; 2003 May; 17(5):859-68. PubMed ID: 12750698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study.
    Reiffers J; Stoppa AM; Attal M; Michallet M; Marit G; Blaise D; Huguet F; Corront B; Cony-Makhoul P; Gastaut JA; Laurent G; Molina L; Broustet A; Maraninchi D; Pris J; Hollard D; Faberes C
    Leukemia; 1996 Dec; 10(12):1874-82. PubMed ID: 8946925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Hengeveld M; Suciu S; Karrasch M; Specchia G; Marie JP; Muus P; Petti MC; Rotoli B; Amadori S; Fioritoni G; Leoni P; Morra E; Thaler J; Resegotti L; Fazi P; Vignetti M; Mandelli F; Zittoun R; de Witte T
    Ann Hematol; 2012 Jun; 91(6):825-35. PubMed ID: 22460947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 75.